The invention provides a novel process for manufacturing a compound of formula (I), or a salt thereof,
The invention provides a novel process for manufacturing a compound of formula (I), or a salt thereof,
The invention provides a novel process for manufacturing a compound of formula (I), or a salt thereof,
wherein PG1, PG2 and PG3 are amino protective groups. The process according to the invention is particularly suitable for large-scale manufacturing under GMP conditions.
C07K 5/09 - Tripeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
C07D 209/20 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
C07D 209/26 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
2.
METHODS FOR VIRAL INACTIVATION AND OTHER ADVENTITIOUS AGENTS
The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The invention relates generally crystalline mesylate salts, crystalline chloride salts and crystalline sulfate salts of the compound(S)-2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino) -6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one that is an inhibitor of Bruton's tyrosine kinase. In some aspects, the crystalline salts are single polymorphs.
A computer-implemented method for performance verification of a thermal block cycler unit for automated thermal treatment of at least one sample is described. The thermal block cycler unit includes at least one thermal block configured for receiving at least one sample vessel, and a plurality of hardware modules. The hardware modules include a plurality of heating and/or cooling elements and at least one temperature sensor. The method includes consecutively functional testing the hardware modules, and defining the order of tests by using a thermal energy of its preceding test and/or a status of the thermal block cycler unit of its preceding test, and balancing energy consumption between the steps to minimize a difference between an input temperature before consecutively testing the hardware modules and an output temperature after consecutively testing the hardware modules.
The application relates to compounds of formula (I) which act as antagonists of STING useful for the treatment of autoimmune diseases, inflammatory diseases, neurological disorders, metabolic diseases, cardiovascular diseases, ocular diseases, or selective types of cancer where overexpression or activation of STING is implicated.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A federated analytics (FA)/federated learning (FL) system configured to implement a federated learning pipeline or a federated analytics pipeline comprises: a centralized FA/FL platform comprising a client environment interface module; and a plurality of local environments, each local environment comprising a respective local memory configured to store local raw data and/or local pre-processed data. The local environments are configured to obtain data from data sources, and to generate local statistical models which are aggregated at the centralized platform to generate a global statistical model, thereby fulfilling a client request.
The present invention relates to a splice variant of an ICA1 protein that acts as a biomarker for a TDP-43 pathology. In particular, the present invention relates to methods for identifying a splice variant of ICA1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject.
An apparatus (200) includes a pair of rigid legs (210) extending parallel with each other along a plane. Each leg of the pair of legs has a sharp tip (215). The apparatus also includes head (210), including a top surface (222), a bottom surface (224), a pair of end surfaces (226), a pair of side surfaces (227), and a guide notch (230) extending upwardly from the bottom surface. The guide notch is configured to cooperate with a surface of a sclera of a patient's eye to define a guide opening that is oriented transversely relative to the plane associated with the legs and that is sized to receive a cannula having a generally flat profile. The head further includes a pair of receptacles (240) extending laterally inwardly from respective side surfaces of the pair of side surfaces. Each receptacle of the pair of receptacles is configured to engage a deployment instrument.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61F 9/013 - Methods or devices for eye surgery for compensation of ocular refraction
A61B 17/10 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for applying or removing wound clampsWound clamp magazines
The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one useful as pharmaceutically active compounds.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A method includes determining, within an image of a biological sample from an intestine of a patient, a plurality of image patches depicting a portion of the biological sample. A plurality of bowel disease indication groups corresponding to a subset of the plurality of image patches may be determined based at least on the plurality of image patches. A group-level histological score for each bowel disease indication group of the plurality of bowel disease indication groups may be generated based at least on the subset of the plurality of image patches contained in each respective group. An aggregated histological score indicative of a disease burden in the intestine of the patient may be generated based on the generated group-level histological score for each bowel disease indication group. Related systems and computer program products are also provided.
G06V 10/762 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using clustering, e.g. of similar faces in social networks
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
The invention provides a compound of formula (I):
The invention provides a compound of formula (I):
The invention provides a compound of formula (I):
or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 have any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a prodrug thereof, or a pharmaceutically acceptable salt thereof. The compounds are agonists of glycolytic enzyme phosphofructokinase-1 liver type and are useful for treating diseases associated with the activity of glycolytic enzyme phosphofructokinase-1 liver type, such as cancer, diabetes, sepsis, and septic shock.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
14.
METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
15.
DETECTING LONGITUDINAL PROGRESSION OF ALZHEIMER'S DISEASE (AD) BASED ON SPEECH ANALYSES
A method implemented by one or more computer device includes detecting longitudinal progression of Alzheimer's disease (AD) in a patient. The method includes receiving speech data including a patient's description of one or more previous or current experiences of the patient, in which the speech data was captured at a plurality of moments during a period of time. The method further includes analyzing the speech data to quantify a plurality of speech variables, in which the plurality of speech variables includes a word-length variable and a use-of-particles variable. The method includes determining a composite score based on a standardization and a substantive weighting assigned to each of the quantified plurality of speech variables. The method thus includes detecting, based on the composite score, a predicted longitudinal change in the quantified speech variables, and further estimating, based on the predicted longitudinal change, a progression of AD for the patient.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
Methods are disclosed for producing a molecule comprising a polypeptide complex formed by interaction between a first polypeptide comprising a CH3 region comprising a knob modification and a second polypeptide comprising a CH3 region comprising a hole modification.
The present invention relates to a method for stabilizing the C3bBb complex, a rapidly decaying component of the alternative pathway of the complement system, and stabilized C3bBb complexes and uses thereof.
The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, U, V, X, Y, L1, R1, and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Systems and methods of prediction of future tumor data. A tumor embedding at a neural ordinary differential equations (ODE) system is received. The tumor embedding is generated using a tumor encoder and observed tumor data that is observed over a selected period of time after a reference point in time. A graph embedding at the neural ODE is received. The graph embedding fuses drug information, disease information, and gene relationship information. The graph embedding is generated using a heterogenous graph encoder that fuses together at least two or more embeddings generated using bipartite graph convolution attention networks. A predicted tumor size at a future point in time is generated using the tumor embedding, the graph embedding, and the neural ODE system. A candidate tumor treatment is administered to a subject in response to the predicted tumor size being less than a selected threshold.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
20.
COMBINATION THERAPY OF ANTI-TYRP1/ANTI-CD3 BISPECIFIC ANTIBODIES AND TYRP1-SPECIFIC ANTIBODIES
The present invention relates to the combination therapy of a bispecific antibody which binds human TYRP1 and CD3 and a second TYRP1-specific antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
21.
ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The invention provides new heterocyclic compounds having the general formula (I) wherein A and R1 to R4 are as described heroin, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
The invention provides new heterocyclic compounds having the general formula (I) wherein A and R1 to R4 are as described heroin, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A method of verifying a program code of a synthesis computer program is disclosed. The synthesis computer program is configured for computer-controlling an automatic synthesizer (114) to automatically synthesize at least one oligonucleotide, the synthesis computer program having a plurality of program cycles for computer-controlling the automatic synthesizer (114) to sequentially synthesize the oligonucleotide by using at least one sequence of synthesis cycles. The method comprises:
i. applying an automatic parsing procedure to the program code of the synthesis computer program, the automatic parsing procedure comprising automatically searching for parameter values of parameters of at least one predetermined list of parameters of interest in the program cycles of the synthesis computer program; and
ii. automatically assembling a matrix of parameters comprising, for the program cycles of the synthesis computer program, the parameters of interest and the corresponding parameter values of the parameters of interest.
A method of verifying a program code of a synthesis computer program is disclosed. The synthesis computer program is configured for computer-controlling an automatic synthesizer (114) to automatically synthesize at least one oligonucleotide, the synthesis computer program having a plurality of program cycles for computer-controlling the automatic synthesizer (114) to sequentially synthesize the oligonucleotide by using at least one sequence of synthesis cycles. The method comprises:
i. applying an automatic parsing procedure to the program code of the synthesis computer program, the automatic parsing procedure comprising automatically searching for parameter values of parameters of at least one predetermined list of parameters of interest in the program cycles of the synthesis computer program; and
ii. automatically assembling a matrix of parameters comprising, for the program cycles of the synthesis computer program, the parameters of interest and the corresponding parameter values of the parameters of interest.
Further disclosed is a computer program and a computer-readable storage medium for performing the method of verifying a program code of a synthesis computer program, a system (110) for verifying a program code of a synthesis computer program and a method of synthesizing at least one oligonucleotide.
This disclosure relates to methods, uses, and compositions (e.g., articles of manufacture and kits) comprising an anti-OSMRβ antibody, such as vixarelimab, for the treatment of inflammatory gastrointestinal diseases associated with the oncostatin M (OSM) pathway (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC (e.g., moderate to severe UC)) and Crohn's disease (CD)).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A computer-implemented method is provided, which determines at a prediction time tp, a likelihood of kidney failure of a patient within an amount of time Δt. The method comprises receiving input data, the input data comprising a recent creatinine level cR or recent eGFR eGFRR, and one or more of the following: (a) an initial creatinine level c0 and either: a time t0 at which the initial creatinine level c0 was measured, or a time interval ΔT0=tp−t0; (b) an initial estimated glomerular filtration rate (eGFR) eGFR0 and either: a time t0 at which the initial eGFR was determined, or a time interval ΔT0=tp−t0; (c) for a plurality of past creatinine level measurements ci measured at a respective times ti, a statistical parameter derived from a linear regression of the plurality of past creatinine level measurements; and (d) for a plurality of past eGFR values eGFRi determined at respective times ti, a statistical parameter derived from a linear regression of the plurality of past eGFR values; and applying a machine-learning model to the input data to generate an output indicating the likelihood of kidney failure within the given amount of time Δt. Corresponding training methods and systems are also provided.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.
A method and system for evaluating a treatment using one or more model parameters associated with a quantitative systems pharmacology (QSP) system. Input data corresponding to a treatment is received. The input data is sent to a machine learning system that has been trained, the machine learning system representing at least a portion of the QSP model. The machine learning system is used to generate a set of values for a set of treatment effect parameters associated with the QSP model. A final output is generated based on an evaluation of the treatment on a subject using the set of values for the set of treatment effect parameters.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
28.
THERMAL CONTROL DEVICE FOR TEMPERATURE CYCLING, METHOD FOR CONTROLLING TEMPERATURE CYCLING USING A THERMAL CONTROL DEVICE, AND SYSTEM FOR CONTROLLING TEMPERATURE OF A SAMPLE USING A THERMAL CONTROL DEVICE
In one embodiment, a thermal control device (110) adapted for temperature cycling is provided. The thermal control device (110) comprises a thermally conductive heat spreader layer (118) comprising a first side surface and a second side surface. A heater circuit (120) is disposed adjacent to and in thermal contact with at least one of the first side surface and the second side surface of the thermally conductive heat spreader layer (118). At least one thermal interface material layer (114) is disposed adjacent to and in thermal contact with one of the first side surface and the second side surface of the thermally conductive heat spreader layer (118). A cooling block (116) is disposed adjacent to and in thermal contact with the thermal interface material layer (114). The cooling block (116) is adapted to conduct heat energy away from the thermally conductive heat spreader layer (118). A controller is coupled to and adapted to control the heater circuit (120). In another embodiment, a diagnostic test device is provided.
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing congestion in a subject comprising the steps of determining in a sample of the subject the amount of a BMP 10-type peptide (Bone Morphogenic Protein 10-type peptide) and comparing the amount of the BMP 10-type peptide to a reference for the BMP 10-type peptide, whereby congestion is to be assessed. The present invention also contemplates a method of differentiating between precapillary pulmonary hypertension and postcapillary pulmonary hypertension. Further, the invention concerns computer-implemented methods of the aforementioned methods as well as devices and kits for carrying out said methods. Yet, the invention in general relates to the use of a BMP 10-type peptide or a detection agent therefor in a sample of a subject for assessing congestion or the use of a BMP 10-type peptide or a detection agent therefor in a sample of a subject for differentiating between precapillary pulmonary hypertension and postcapillary pulmonary hypertension.
The current invention is directed to a method for determining homodimeric avid-binding side-products of a bispecific antibody in a sample comprising the correctly assemble heterodimeric affine-binding bispecific antibody and the mis-assembled homodimeric avid-binding side-product of the bispecific antibody using surface plasmon resonance, wherein the correctly assembled heterodimeric affine-binding bispecific antibody comprises one or more binding site for a first antigen and one or more binding sites for a second antigen, wherein the mis-assembled homodimeric avid-binding side-product of the bispecific antibody comprises two or more binding sites to the first antigen but at least more than the correctly assembled bispecific antibody, wherein the correctly assembled bispecific antibody is a heterodimer and the mis-assembled bispecific antibody is a homodimer, wherein the presence of the homodimeric avid-binding side-product is determined if residual binding, i.e. an increased SPR signal, can be determined in the dissolution phase of the SPR analysis.
The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
34.
FOLR1 PROTEASE-ACTIVATABLE T CELL BISPECIFIC ANTIBODIES
The present invention generally relates to improved Protease-activatable antigen-binding molecules that comprise an anti-idiotype-binding moiety which reversibly masks a CD3 antigen binding moiety of the molecule. Furthermore, the invention relates to novel Protease-cleavable peptide linkers and their used in such Protease-activatable antigen-binding molecules. In addition, the present invention relates to polynucleotides encoding such Protease-activated T cell binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the Protease-activated T cell binding molecules of the invention, and to methods of using the same, e.g., in the treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Methods for facilitating selection of cell lines for production of recombinant proteins are disclosed. In particular, disclosed is the use of machine learning models trained on multiomics data to predict one or more values indicative of the titre and/or quality of a recombinant protein expressed by different cell lines, enabling ranking the cell lines based on the predicted values and selecting those predicted to produce the recombinant protein with higher titre and/or higher quality.
A computer-implemented training method (110) of training at least one trainable model is disclosed for classifying a patient's health condition into a systemic inflammatory state (168, 170, 172) selected from a predetermined group of at least three systemic inflammatory states (168, 170, 172). The method comprises: a. providing the trainable model; b. retrieving labeled training patient data, the training patient data comprising gene expression data of patients having known systemic inflammatory states (168, 170, 172); and c. training the trainable model on the labeled training patient data. Further disclosed is a computer-implemented classification method (112) of classifying a patient's health condition into a systemic inflammatory state (168, 170, 172) selected from a predetermined group of at least three systemic inflammatory states (168, 170, 172) and systems, computer programs and computer-readable storage media for performing the methods.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present invention relates to the field of diagnostics. In particular, it relates to a method for assessing systemic inflammation in a subject exhibiting symptoms thereof comprising a) determining in a sample of said subject the amounts of biomarkers from a group of biomarkers selected from i) a first group of biomarkers comprising: POMK, NEK6, KCNA5, LARGE2, ZNF425, NACA2, CFAP57, SPINT1, ZNF492, and S100A6, ii) a second group of biomarkers comprising: NEK6, SRPK3, TNFSF8, S100A6, NMUR1, DHFR, HIST1H4D, ZDHHC4, TRAF3, and SGMSlor iii) a third group of biomarkers comprising: C9orfl35, ZNF425, ACOT4, SPDYA, DAPP1, LY86, ZPBP2, RPL3L, UPK1B, and APBB3, b) comparing said determined amounts of biomarkers from said group of biomarkers to a reference, and c) assessing systemic inflammation in the subject. Further, the present invention, in general, relates to the use of the amounts of said biomarkers in a sample of a subject exhibiting symptoms of systemic inflammation for assessing systemic inflammation. Moreover, contemplated are a device and a kit for assessing systemic inflammation.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Methods for selecting cell pools for production of recombinant proteins are disclosed. In particular, disclosed is the use of one or more genes whose expression level can be used as a biomarker to predict which cell pool, among a plurality of cell pools, produces a recombinant protein with higher titre and/or higher quality.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
43.
PROCESS FOR THE PREPARATION OF 7-(4,7-DIAZASPIRO[2.5]OCTAN-7-YL)-2-(2,8-DIMETHYLIMIDAZO[1,2-B]PYRIDAZIN-6-YL)PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES
The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Exemplary systems and methods are provided for receiving a feed flow at a feed flow inlet of a single pass tangential flow filtration unit, wherein the single pass tangential flow filtration unit includes one or more membranes or membrane devices in a one-or two-stage configuration, and wherein a pressure drop across the one or more membranes or membrane devices is less than or equal to 30 psi. The systems and methods are configured to separate, using the one or more membranes or membrane devices in a one-or two-stage configuration, the feed stream into a permeate stream and a retentate stream and output the permeate stream through one or more permeate outlets and the retentate stream through one or more retentate outlets.
The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
46.
METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
47.
LOW CONCENTRATION SINGLE PASS TANGENTIAL FLOW FILTRATION TO DE-BOTTLENECK CONNECTED AND/OR HIGH TITER FED BATCH PROCESSES
Exemplary systems and methods are provided for receiving a feed flow at a feed flow inlet of a single pass tangential flow filtration unit, wherein the single pass tangential flow filtration unit includes one or more membranes or membrane devices in a one- or two-stage configuration, and wherein a pressure drop across the one or more membranes or membrane devices is less than or equal to 3Opsi. The systems and methods are configured to separate, using the one or more membranes or membrane devices in a one- or two-stage configuration, the feed stream into a permeate stream and a retentate stream and output the permeate stream through one or more permeate outlets and the retentate stream through one or more retentate outlets.
Methods for preparing the Bruton's Tyrosine Kinase (“BTK”) inhibitor compound 2-{3′-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to systems and methods to detect liver cirrhosis in digital images. Various embodiments of the present invention relate to systems and methods to detect liver cirrhosis in computed tomography (CT) scans and, more specifically but not limited, to systems and methods to detect liver cirrhosis via a model trained on highly-interpretable features.
Methods for facilitating selection of cell lines for production of recombinant proteins are disclosed. In particular, disclosed is the use of machine learning models trained on multiomics data to predict one or more values indicative of the titre and/or quality of a recombinant protein expressed by different cell lines, enabling ranking the cell lines based on the predicted values and selecting those predicted to produce the recombinant protein with higher titre and/or higher quality.
The present invention generally relates to chimeric receptors comprising an extracellular domain comprising a mutated Fc domain. The invention also relates to transduced immune cells expressing the chimeric receptors of the invention and/or nucleic acid molecules encoding the chimeric receptors of the present invention. Further provided are kits comprising such cells and/or nucleic acid molecules encoding the chimeric receptors, and antibodies capable of binding to the chimeric receptors.
The present disclosure provides high viscosity ultrafiltration/diafiltration (UF/DF) and single-pass tangential flow filtration (SPTFF) processes used in the purification of polypeptides. A method for purifying a polypeptide from a polypeptide preparation may include the following steps in order: a) subjecting the polypeptide preparation to one or more purification processes and recovering a first resulting pool having a viscosity of about 5-40 cP; and b) subjecting the pool recovered from step a) to a SPTFF operation comprising use of membranes in either or both a serial membrane and/or a parallel membrane configuration and recovering a second resulting pool having an operating viscosity of about 41-400 cP, wherein, i) the operating temperature is about 15-55° C., and ii) the feed flux is about 5-50 L/m2/hr (LMH).
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
53.
TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3, 2-F][1, 2, 4]TRIAZOLO[4, 3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER
The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.
In one aspect, a method for identifying residues in a particular conformation of a protein molecule capable of forming a stable binding between a compound and the protein molecule is provided. The method can include identifying, for inclusion in a perturbation set, one or more residues from the conformation of the protein molecule that exhibit a protection factor satisfying one or more thresholds. One or more residues may be excluded from the perturbation set based at least on a spatial arrangement and/or an orientation of the one or more residues. One or more rounds of molecular dynamics simulations whose result is indicative of an interaction between the compound and the residues in the perturbation set may be performed. The residues in the perturbation set may be identified as forming a stable binding between the compound and the protein molecule based at least on the result of the molecular dynamics simulation
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07D 205/02 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07D 295/10 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The invention relates to a laboratory device (1) for handling laboratory sample container racks (50), the laboratory device (1) comprising a base (2) extending horizontally, the base (2) being adapted to support laboratory sample container racks (50) placed thereon, a first finger (3) being movable relative to the base (2), the first finger (3) being adapted to position a laboratory sample container rack (50) on the base (2), a second finger (4) being adapted to horizontally counteract the first finger (3) so that the laboratory sample container rack (50) positioned on the base (2) is holdable in between the first finger (3) and the second finger (4), a down-holder (5) being movable relative to the base (2), the down-holder (5) being adapted to releasably vertically secure the laboratory sample container rack (50) positioned on the base (2), and a linkage (6) which motion-couples the first finger (3) and the second finger (4) and the down-holder (5) to one another.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
A transfer method and a transfer device (110) for transferring at least one volume of a cell suspension from a first sample tube (112) to a second sample tube (114) are disclosed. The transfer device (110) comprises: - at least one first cannula (116) configured for transferring the at least one volume of the cell suspension from the first sample tube (112) to the second sample tube (114), wherein the first cannula (116) comprises at least one first cannula tip (118) configured for at least partially penetrating into an interior (120) of the first sample tube (112), wherein the first cannula (116) further comprises at least one second cannula tip (122) configured for at least partially penetrating into an interior (124) of the second sample tube (114), wherein the first cannula tip (118) and the second cannula tip (122) are in direct fluidic connection (126) with each other, enabling a transfer of the at least one volume of the cell suspension from the first sample tube (112) to the second sample tube (114); and - at least one second cannula (130) configured for providing at least one pressure port (132) to the interior (120) of the first sample tube (112).
The present disclosure provides high viscosity ultrafiltration/diafiltration (UF/DF) and single pass tangential flow filtration (SPTFF) processes used in the purification of polypeptides. A method for purifying a polypeptide from a polypeptide preparation may include the following steps in order: a) subjecting the polypeptide preparation to one or more purification processes and recovering a first resulting pool having a viscosity of about 5-40 cP; and b) subjecting the pool recovered from step a) to a SPTFF operation comprising use of membranes in either or both a serial membrane and/or a parallel membrane configuration and recovering a second resulting pool having an operating viscosity of about 41-400 cP, wherein, i) the operating temperature is about 15-55°C, and ii) the feed flux is about 5-50 L/m2/hr (LMH).
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical preparations for scientific purposes, other than for medical or veterinary use; Biological preparations, other than for medical or veterinary purposes; Biochemical preparations for scientific purposes; Diagnostic reagents for scientific or research use; Reagents for use in scientific apparatus for chemical or biological analysis; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes; Nucleic acids for scientific purposes; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Chemical reagents for use in genetic research.
The invention provides new heteroaromatic compounds having the general formula (I′), or a solvate or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, and n are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
The invention provides new heteroaromatic compounds having the general formula (I′), or a solvate or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, and n are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/4433 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
The present invention provides novel compounds having the general formula:
The present invention provides novel compounds having the general formula:
The present invention provides novel compounds having the general formula:
wherein ring A, ring B, ring C, bond a, and R1 to R7 are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
In one example, a method being performed by a computer system comprises: receiving an image file containing a pathology report; performing an image recognition operation on the image file to extract input text strings; detecting, using a natural language processing (NLP) model, entities from the input text strings, each entity including a label and a value; extracting, using the NLP model, the values of the entities from the input text strings; converting, based on a mapping table that maps entities and values to pre-determined terminologies, the values of at least some of the entities to the corresponding pre-determined terminologies; and generating a post-processed pathology report including the entities detected from the input text strings and the corresponding pre-determined terminologies.
G06V 30/30 - Character recognition based on the type of data
G06V 30/416 - Extracting the logical structure, e.g. chapters, sections or page numbersIdentifying elements of the document, e.g. authors
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
The present invention relates to a method for the generation of single stranded DNA (ssDNA) molecules from circular double stranded DNA (dsDNA) molecules.
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
69.
TREATMENT OF NON SMALL CELL LUNG CANCER WITH ALECTINIB
The present invention relates to a method of treating anaplastic lymphoma kinase (ALK)- positive non-small cell lung cancer (NSCLC), comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject has resected stage Ib ALK-positive NSCLC with a tumour greater or equal to 4cm to stage IIIa ALK-positive NSCLC.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A CCI testing system (1) to test closure integrity of a container (2) with a hollow interior (223), an outlet (221), an open end (222) and a stopper (21) arranged to close the hollow interior (223), comprises a container holder (13), a test gas supply (171), a test gas detector (11) and a chamber (14). The container holder (13) is configured to tightly receive a first aperture being one of the open end (222) of the container (2) or the outlet (221) of the container (2). The test gas supply (171) comprises a test gas. The test gas detector (11) is tightly coupled to the container holder (13) and configured to detect test gas exiting the first aperture when being received by the container holder (13). The chamber (14) is coupled to the container holder (13) to form an encasing of a second aperture being the other one of the open end (222) of the container (2) or the outlet (221) of the container (2) when the first aperture is received by the container holder (13). The test gas supply (171) is coupled to the chamber (14). The test gas detector (11) is configured to apply a subatmospheric pressure to the container holder (13) and the container holder (13) is configured to effect the subatmospheric pressure to the first aperture. The test gas supply (171) is configured to supply test gas into the chamber (14). The chamber (14) has an exhaust outlet (141). The chamber (14) is configured to expose the second aperture to a gas flow generated by the test gas supply (171) supplying test gas into the chamber (14) and out of the chamber (14) via the exhaust outlet (141), when the first aperture is received by the container holder (13).
G01M 3/20 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material
G01M 3/22 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material for pipes, cables, or tubesInvestigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material for pipe joints or sealsInvestigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material for valves
G01M 3/28 - Investigating fluid tightness of structures by using fluid or vacuum by measuring rate of loss or gain of fluid, e.g. by pressure-responsive devices, by flow detectors for pipes, cables, or tubesInvestigating fluid tightness of structures by using fluid or vacuum by measuring rate of loss or gain of fluid, e.g. by pressure-responsive devices, by flow detectors for pipe joints or sealsInvestigating fluid tightness of structures by using fluid or vacuum by measuring rate of loss or gain of fluid, e.g. by pressure-responsive devices, by flow detectors for valves
72.
TERTIARY PYRIDYL AMINE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYLINATION
The subject matter described herein is directed to myelin-promoting compounds of Formula A and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
73.
SEMI-AUTOMATED HIGH-THROUGHPUT MID-SCALE PROTEIN EXPRESSION METHODS
The present disclosure relates to a higher-throughput, mid-scale, semi-automated protein expression and screening platform that can be used, for instance, for drug discovery research and otherwise for testing protein expression conditions, among other uses. The workflow described here also in some embodiments enables comprehensive expression and purification screening assessment of challenging or difficult-to-express recombinant proteins in a faster and efficient manner by delivering small but sufficient amounts of high-quality proteins.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemical preparations for scientific purposes, other than
for medical or veterinary use; diagnostic preparations for
research laboratory use; diagnostic reagents for scientific
or research use; biochemicals, namely, monoclonal antibodies
for in vitro scientific or research use; diagnostic reagents
for in vitro use in biochemistry, clinical chemistry and
microbiology; calibration fluids for medical apparatus;
testing kit comprising reagents for conducting enzyme-linked
immunosorbent assays (elisa) [other than for medical or
veterinary purposes].
75.
Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists
Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% m 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (TRD) and Fragile X Syndrome.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The subject matter described herein is directed to molecules referred to herein as chemical inducers of degradation (CIDEs) and antibody-conjugated CIDEs (Ab-CIDEs), wherein the Ab-CIDEs comprise an antibody covalently bound to the CIDE through a linker, wherein the CIDE can be further covalently bound to a phosphate moiety, and to the uses of the molecules in treating diseases and conditions where targeted protein degradation is beneficial.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
77.
METHODS AND DEVICES FOR MANAGING INFORMATION DEALING WITH A MEDICAL TEST FOR ASSESSING A PREDETERMINED MEDICAL CONDITION
The invention relates to a method for managing information dealing with a medical test for assessing a predetermined medical condition by means of a distributed system (100) comprising a plurality of communication devices (210, 312, 322, 410), the method comprising obtaining by a user communication device (210) information on an access code provided in a test-kit for assessing a predetermined medical condition, the user communication device (210) being configured for receiving and displaying messages addressed to a unique identifier. Further, the method comprises providing instructions relating to analysis of the medical sample. A negative analysis result is communicated to the user communication device (210) of the user. In case of a positive analysis result, consultation by a medical entity is established. Further aspects relate to a user communication device, a computer program product, a central server and a medical test-kit for use with the proposed method.
G01N 33/487 - Physical analysis of biological material of liquid biological material
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
78.
PYRAZOLE DERIVATIVES AS SARM1 INHIBITORS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
The invention provides compounds having the general formula (I) wherein X, Y, Z, and R1to R8a are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds in the treatment or prevention of diseases that are associated with SARM1.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 25/00 - Drugs for disorders of the nervous system
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A CCI testing method to test physical container closure integrity of a container (2), comprises the steps of: (120) obtaining a container having a hollow interior, an outlet, an open end and a stopper arranged to close the hollow interior; (121) tightly connecting a first aperture being one of the outlet of the container and the open end of the container to a test gas detector; (122) connecting a second aperture being the other one of the outlet of the container and the open end of the container to a test gas supply; (123) arranging the test gas detector to apply a detector pressure at the first aperture; (124) arranging the test gas supply to provide test gas at a first test gas pressure to the second aperture; (125) measuring test gas at the first aperture by means of the test gas detector while the test gas is provided at the first test gas pressure; (126) determining a first leakage rate based on the test gas measured at the first test gas pressure; and (127, 128, 129) determining a second leakage rate at a second pressure. A first pressure difference being a difference between the first test gas pressure and the detector pressure differs from a second pressure difference being a difference between the second pressure and the detector pressure.
G01M 3/20 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material
80.
NOVEL METHODS FOR PREPARING SEMI-SOLID COMPOSITIONS AND USES THEREOF
The present application discloses methods and uses for preparation of a dry solid composition as a precursor for a stable gel body formation upon addition of water. The invention also discloses the compositions obtained from said methods and uses. Said gel bodies can, for example, be used in pharmaceutical compositions to administer drug substances to patients with difficulties to swallow.
A navigable directed graph interface representing a medical guideline, wherein the medical guideline includes a decision tree including a plurality of clinical decisions and preconditions. The navigation interface presents a portion of the directed graph based on a sequence of recorded preconditions and/or clinical decisions of the medical guideline and a portion of the directed graph diverging from the sequence of recorded preconditions and/or clinical decisions. The diverging portion of the directed graph is graphically distinguished from the portion of the directed graph based on the recorded preconditions and/or clinical decisions. In response to receiving a selection of an alternate node from the diverging portion of the directed graph, the graphical representation of the directed graph displays one or more child nodes of the selected alternate node.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 70/20 - ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
82.
METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER COMPRISING AN ANTI-TIGIT ANTAGONIST ANTIBODY AND A PD-1 AXIS BINDING ANTAGONIST
The present disclosure relates to the treatment of non-small cell lung cancer (NSCLC). More specifically, the disclosurerelates to the treatment of patients having an NSCLC by administering a treatment regimen that includes an anti-TIGIT antagonist antibody (e.g., tiragolumab) and a PD-1 axis binding antagonist (e.g., atezolizumab) following surgical resection and adjuvant chemotherapy or by administering a treatment regimen that includes an adjuvant chemotherapy, an anti-TIGIT antagonist antibody (e.g., tiragolumab), and a PD-1 axis binding antagonist (e.g., atezolizumab) following surgical resection.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
This disclosure relates to methods, uses, and compositions (e.g., articles of manufacture and kits) comprising an anti-OSMRβ antibody, such as vixarelimab, for the treatment of inflammatory gastrointestinal diseases associated with the oncostatin M (OSM) pathway (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC (e.g., moderate to severe UC)) and Crohn's disease (CD)).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma (DLBCL)) using immunoconjugates comprising anti-CD79b antibodies in combination with an anti-CD20 antibody (such as rituximab) and one or more chemotherapeutic agents (such as gemcitabine and oxaliplatin).
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
86.
METHOD FOR CHARACTERIZATION OF A MASS SPECTROMETRY INSTRUMENT COMPRISING AT LEAST ONE MASS ANALYZING CELL
A method for characterization of a mass spectrometry instrument (100) comprising at least one mass analyzing cell (102, 104, 106) is proposed. The method comprising the steps of analyzing a sample (110) comprising at least one substance having a known molecular weight by means of the mass spectrometry instrument (100) so as to provide a mass spectrum (116, 118, 144, 146) of the sample (110), determining an outer envelope and an inner envelope of the mass spectrum (116, 118, 144, 146), calculating a squared difference between the outer envelope and the inner envelope, and determining a deviation of the calculated squared difference from a theoretical mass to charge ratio value of the substance.
A method for operating a laboratory system having a plurality of sample containers; a plurality of laboratory devices to handle the sample containers, the sample containers being assigned for handling to the target device; and a control device configured to control assignment of the sample containers to the target devices; and assigning the sample containers. The assigning comprises: determining a target device workload state for each target device, the workload state being between a first range limit and a second range limit, and determined according to a metric being proportional to a resource target device state indicative of sample containers assigned to the target device, and a power of an output flow of the target device, assigning the sample containers to the target devices according to the target device workload states; and providing sample containers to the plurality of target devices. Furthermore, a laboratory system is provided.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G06Q 10/0631 - Resource planning, allocation, distributing or scheduling for enterprises or organisations
G06Q 10/0639 - Performance analysis of employeesPerformance analysis of enterprise or organisation operations
88.
METHOD FOR OPERATING A SORTER DEVICE IN AN IVD LABORATORY SYSTEM AND IVD LABORATORY SYSTEM
The present disclosure refers to a method for operating a sorter device in an IVD laboratory system, the method comprising providing a sorter device in an IVD laboratory system provided with a system operation controller, the sorter device having a plurality of sample container racks each provided with reception holes for receiving sample containers, a handling device configured to pick sample containers from and place sample containers in the reception holes of the sample container racks, a sorter device controller configured to control operation of the sorter device and connectable to the system operation controller, and an output device functionally connected to the sorter device controller and configured to output at least one of audio data and video data. The sorter device is configured in a pre-operation process, the configuring comprising: assigning the plurality of sample container racks to a plurality of processing sub-targets conducted by the IVD laboratory system in operation, wherein a first sample container rack is assigned to a first processing sub-target and a second sample container rack is assigned to a second processing sub-target which is different from the first processing sub-target, and assigning to the first sample container rack a first threshold value indicative of a first threshold number of sample containers in the first sample container rack, wherein the first threshold number of sample containers is smaller than a maximum number of sample containers receivable in the first sample container rack. The sorter device is operated in an operation process, the operating comprising: placing sample containers in the reception holes of the first sample container rack by the handling device, determining a first present number of sample containers received in the first sample container rack by the sorter device controller, comparing the first present number of sample containers to the first threshold value by the sorter device controller, and if the first present number of sample containers is equal to or greater than the first threshold value, outputting a first warning data through the output device. Furthermore, an IVD laboratory system is provided.
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The invention provides a compound represented by represented by the following structural formula:
The invention provides a compound represented by represented by the following structural formula:
or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The present invention relates generally to glutamine-free cell culture media supplemented with arginine. The invention further concerns the production of recombinant proteins, such as antibodies, in arginine-supplemented glutamine-free mammalian cell culture.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Automated methods for genotyping melting curves are described. Melting curves are processed and difference matrices are compiled based on the processed matrices. The difference matrices are used to compile a cluster matrix and the cluster matrix is filtered to determine clusters that are used for genotyping the melting curves.
There is disclosed a method and sensor for detecting a plurality of analytes in bodily fluid, the sensor comprising electrodes including a first working electrode, a second working electrode, a third working electrode, a counter electrode, and a reference electrode; wherein the first working electrode is configured to detect a first signal indicative of a first analyte concentration using potentiometry; wherein the second working electrode is configured to detect a second signal indicative of a second analyte concentration using amperometry; wherein the third working electrode is configured to detect a third signal indicative of a third analyte concentration using amperometry; wherein the first analyte, the second analyte, and third analyte are different analytes; wherein the first signal, the second signal, and the third signal are detected using the same reference electrode; wherein at least part of the detection of the first signal occurs simultaneously with the detection of the second signal; wherein the second signal and third signal are detected using the same counter electrode; wherein at least part of the detection of the second signal occurs simultaneously with the detection of the third signal; and wherein at least one of the second working electrode and third working electrode is continuously polarized by application of a polarization voltage during detection of the first signal, second signal and third signal.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1468 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means
G01N 27/27 - Association of two or more measuring systems or cells, each measuring a different parameter, where the measurement results may be either used independently, the systems or cells being physically associated, or combined to produce a value for a further parameter
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
G01N 33/487 - Physical analysis of biological material of liquid biological material
A61B 5/1495 - Calibrating or testing in vivo probes
G01N 33/62 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving urea
G01N 33/64 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving ketones
G01N 33/98 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving alcohol, e.g. ethanol in breath
94.
DIOXOPIPERIDINE-INDOLONE-METHYLENE-CARBAMATE COMPOUNDS AS DEGRADERS OF CYCLIN-DEPENDENT KINASE 2
The present application provides bicyclic compounds of formula (I), formula (II), and formula (III), and pharmaceutically acceptable salts thereof, that are degraders of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The invention relates to Her2 targeting 4-1BB agonists, in particular 4-1BBL trimer-containing antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Her2 and their use in the treatment of cancer as well as their use in combination with T-cell activating anti-CD3 bispecific antibodies.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.
C07D 491/12 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains three hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
97.
METHOD FOR PREPARING ACID RESISTANT MAGNETIC PARTICLES AND ACID RESISTANT MAGNETIC PARTICLES
In a first aspect, the invention relates to a method for preparing a magnetic bead comprising at least one magnetic particle (M) and a silica coating, wherein the silica coating comprises at least two silica layers, the method comprising steps (a) to (d), wherein at least one of steps (b), (c) and (d) is/are done under sonication, wherein sonication is done with an amplitude (peak-to-peak) in the range of from 50 to 250 μm. A second aspect of the invention is related to a magnetic bead comprising (i) at least one magnetic particle (M) and (ii) a silica coating, wherein the silica coating comprises at least two silica layers; wherein the magnetic bead is stable against 7.5 M hydrochlorid acid and has a metal (cation) leaching rate in 7.5 M hydrochloric acid in the range of from 0.1 to 10%, wherein the metal (cation) leaching is determined according to a complex formation of Fe2+ with bathophenanthroline according to Reference Example 8.2. In a third aspect, the invention relates to a functionalized magnetic bead comprising at least one, magnetic bead according to the second aspect, wherein an outer silica layer is functionalized with at least one group selected from the group consisting of amino group, azide group, alkyne group, carboxyl group, thiol group, epoxy group, aryl group and alkyl group. A fourth aspect of the invention is directed to a process for functionalizing a magnetic bead according to the second aspect comprising at least one magnetic particle (M) and a silica coating, wherein the silica coating comprises at least two silica layers. A fifth aspect of the invention is related to a method for preparing magnetic Fe3O4 supra particles and a sixth aspect relates to the use of a magnetic bead according to the second aspect or of a functionalized according to the fourth aspect for immobilization of acid stable biocatalysts or for solid-phase organic synthesis using acid-stable linker.
H01F 1/33 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials mixtures of metallic and non-metallic particlesMagnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials metallic particles having oxide skin
H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties
H01F 1/34 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of soft-magnetic materials non-metallic substances, e.g. ferrites
98.
ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF
The subject matter described herein relates generally to hydrolysable maleimide-containing molecules that are useful as linkers to covalently bind chemical inducers of degradation to antibodies and to the conjugates produced therefrom and their uses to treat conditions, and to the uses of the conjugates in treating diseases and conditions where targeted protein degradation is beneficial.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I):
Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I):
Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention generally relates to novel protease activatable Fc domain binding molecules, polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the molecules of the invention, and to methods of using these molecules in the treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin